Ge discovery 670 pro

Perchlorate (600mg) was administered prior to ^99mTc-MAA-injection (TechneScan®LyoMAA, Mallinckrodt Pharmaceuticals, Surrey, GB).^99mTc-MAA (avg. 132.7 ± 37.8 MBq, for further details see Table 1) was injected as 1ml single bolus over 5 seconds into the arterial branches supplying the liver area to be treated, and flushed by 5ml saline (one-sided MAA-application in 6/34 patients). SPECT/CT was performed with a dual-headed SPECT/CT gamma camera (GE Discovery 670 Pro®; GE Healthcare, Chicago Il, USA) within one hour from ^99mTc-MAA-injection (SPECT/CT scan parameters are shown in Table 2). CT was performed for anatomical mapping and attenuation correction.
SPECT-images were reconstructed with an OSEM iterative reconstruction protocol (2 iterations, 10 subsets). Quantitative SPECT/CT data were post processed with a dedicated software algorithm (Evolution®, GE Healthcare, Chicago, USA) and co-registered with CT images (GE Xeleris 3®, GE Healthcare, Chicago, USA).

Based on the previous reference dose [10 (link), 14 (link), 15 ], [^99mTc]Tc-HFAPi was administered intravenously in amounts ranging from 790.4 to 930.2 MBq (21.36 to 25.14 mCi). For dynamic biodistribution, whole-body planar scintigraphy was performed at 10, 30, 90, 150 and 240 min in four representative patients. Base on biodistribution results, [^99mTc]Tc-HFAPi imaging was performed 60–90 min following tracer injection in all the patients to get whole-body planar scintigraphy as well as SPECT/CT tomography fusion images. Whole-body scans were performed via GE Discovery 670 pro scanner system (GE Healthcare) equipped with low-energy high-resolution (LEHR) collimators in 18 cm/min velocity. Low-dose CT was performed for attenuation correction and anatomic localization. The patients were asked to self-report any abnormalities at 30 min after the examination was completed.